Apr 18,2018

Feel Therapeutics Closes Seed Round to Change the Way We Manage Mental Health

Feel Therapeutics, Inc., a developer of artificial emotional intelligence technology that changes the way we monitor and manage mental health, today announced that it has raised a total of $1.8 million in seed funding from Anthemis Exponential Ventures, SOSV, Make in LA and angel investors.

FUNDING SEED ROUND
View Analyst & Ambassador Comments
Go to original news
Mar 09,2020

Feel Mental Health program: New partnership with leading insurance organisations, SCOR and Gothaer Life Insurance

Feel Therapeutics, Inc., today announced a partnership with German insurance provider Gothaer Life Insurance and SCOR, the world’s fourth largest reinsurer. The partnership’s aim is to use Feel to prevent and treat occupational disability caused by mental health disorders such as stress or burn-out. Feel comprises four components: the Feel Emotion Sensor, an emotion tracking wearable device that detects and quantifies a person’s emotional changes, the Feel mobile app which responds to those changes and deploys real-time interventions, weekly sessions with an assigned licensed psychotherapist, and access to an online library of tools and exercises.

COLLABORATION PARTNERSHIP

#insurance

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
May 07,2020

Physiological data collected from Feel Program reveals negative emotions have almost doubled since lockdown

Feel Therapeutics has used objective data collected from physiological signals detected by their proprietary Feel Emotion Sensor, an emotion tracking wearable device, to understand and quantify the changes to the emotional states of a sample group of participants in Europe and the USA. Over the course of eight weeks, between February and April 2020, Feel collected data from a random sample group of participants in Europe and the USA, and analysed 128 million electro-dermal activity (EDA) samples, 400 million heart rate variability (HRV) samples, 64 million skin temperature (ST) samples, and approximately 900 significant emotional moments. Results from this recent study showed sudden and significant changes to those physiological signals, indicating that emotional changes or new emotions were being experienced.

CLINICAL STUDY

#connected device

View Analyst & Ambassador Comments
Go to original news
Dec 10,2020

Janssen selected Feel Therapeutics for new accelerator focused on predictive diagnostics and precision treatment

Feel Therapeutics, Inc., was recently selected as an awardee of the prestigious Janssen Digital Solutions QuickFire Challenge to submit solutions with the potential to scale for impact across EMEA within the next five years. Janssen, the pharmaceutical company of Johnson & Johnson, is driven by a desire to prevent disease and will help Feel Therapeutics with resources needed to maximize the potential of developing new, outcomes-focused solutions. Feel will receive residency at the iPEPS incubator for nine months as well as mentoring and coaching from Janssen, with access to commercial expertise and connections.

COLLABORATION PARTNERSHIP

#r&d

#digital biomarkers

#connected device

View Analyst & Ambassador Comments
Go to original news
Jan 12,2021

Feel Therapeutics partnership with SCOR and Gothaer received the Digital Insurance’s Thought Leader Award

The collaboration between Feel Therapeutics, Inc., SCOR and Gothaer has been recognized with the Thought Leader Award 2020 at the “Digital Insurance conference”, an event supported by Süddeutsche Zeitung & Google in Germany. The independent board of Trustees was looking for innovative concepts that bring new things to insurance customers and focus on real relief and service improvement. Feel's partnership with insurance leaders Gothaer Life Insurance and SCOR uses the Feel Program to prevent and treat occupational disability caused by mental health disorders, such as stress or burn-out. The company shared that this partnership has exceeded expectations in both interest and engagement in the program, with 75% of participants completing the program and taking part in all online coaching sessions, showcasing the need for preventative mental health solutions.

View Analyst & Ambassador Comments
Go to original news
Jun 19,2021

Feel Therapeutics partners with academia & innovation experts in the HEART Project for Health & Well-being in Urban Environment

Feel Therapeutics, Inc., announced their participation in the HEART project, coordinated by the National Technical University of Athens (NTUA). The project kicked off with 18 partners from academia and different fields of expertise. The acronym HEART comes from the very philosophy of this urban-health and well-being inspired project’s title: HEAlthier cities Through blue-green Regenerative Technologies. The Feel Emotion Sensor will be used to monitor and assess the impact of the Blue-Green-based interventions on hundreds of participants across these three cities. The Feel Emotion Sensor is a wearable mental health device that uses proprietary algorithms to continuously monitor a person’s emotional state.

CLINICAL STUDY

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Sep 22,2022

Feel Therapeutics Launches its Ground-breaking Digital Precision Medicine Platform to Enable the Era of Precision Neuroscience and Psychiatry

Feel Therapeutics Inc. today announced the launch of its Digital Precision Medicine Platform. Through its proprietary platform, Feel is able to collect clinically valuable data points passively and on a 24/7 basis to generate real-world evidence (RWE) and discover novel digital biomarkers and endpoints. The Digital Precision Medicine Platform combines physiological data gathered through Feel’s Data Monitoring Device with digital data gathered from the Feel Mobile app. Their proprietary Data Monitoring Device monitors physiological signals to detect changes in an individual’s mood, stress, sleep, and a variety of other mental health metrics and markers. At the same time, the Feel Mobile app passively collects information through mobile phone sensors (for example accelerometer and GPS) as well as voice and text data provided by the user, and a number of electronic patient reported outcomes (ePROs) and electronic Clinical Outcome Assessments (eCOAs).

PRODUCT

#connected device

#mobile app

#digital biomarkers

View Analyst & Ambassador Comments
Go to original news
Oct 20,2022

Feel Therapeutics Granted US Patent for its Emotion Detection Technology

Feel Therapeutics Inc., today announced the recent granting by the United States Patent and Trademark Office of US Patent No. 11,410,682 entitled “Method for detecting and recognizing an emotional state of a user”. The emotion detection technology developed by Feel Therapeutics is based on advanced machine learning and signal processing algorithms and methods. These algorithms analyze vital signs and identify patterns that correspond to specific emotions to offer personalized support or therapeutic interventions.

PRODUCT

#connected device

#mobile app

#digital biomarkers

View Analyst & Ambassador Comments
Go to original news
May 09,2023

Feel Therapeutics Selected to Join Johnson & Johnson Innovation–JLABS to Catalyze their Vision of Digital Precision Medicine in Mental Health

Feel Therapeutics, a leading digital precision medicine company, is proud to announce that it has been accepted into Johnson & Johnson Innovation–JLABS. JLABS is a global life science network designed to catalyze transformational solutions across the pharmaceutical, medical device, and consumer health sectors. Feel Therapeutics launched its Digital Precision Medicine Platform in September 2022 to usher in the era of precision neuroscience and psychiatry. The platform is an ecosystem that integrates digital measurement with patient support and programs developed to create physiological and digital biomarkers and therapeutics for mental health.

COLLABORATION PARTNERSHIP

#r&d

#connected device

#digital biomarkers

View Analyst & Ambassador Comments
Go to original news
Aug 18,2023

Welt, Aimmed face delays in launching Korea's first approved DTx devices

Korea approved two digital therapeutics (DTx) devices this year but there has been no news about the market launch since the Ministry of Food and Drug Safety (MFDS) granted the approval for these innovative devices from Aimmed and Welt in February and April this year respectively. As the developers of the first approved DTx devices in Korea, both Welt and Aimmed are exploring uncharted territory. However, even after receiving approval, both companies have to prepare for the pilot project to accumulate real-world evidence of the DTx device, as required by the National Evidence-based Healthcare Collaborating Agency (NECA). Welt CEO Sean Kang expressed his frustration with the slow launch saying that it was being delayed as they were required to jump through several hoops to undergo a pilot project.

#cbt

#pdt

View Analyst & Ambassador Comments
Go to original news
Subscribe to MENTAL HEALTH